Pablo Arias

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

William T. Cefalu, Lawrence A. Leiter, Kun‐Ho Yoon et al. · The Lancet · 2013 · 724 citations

Medicine, Endocrinology, Pharmacotherapy +15

Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study

Lawrence A. Leiter, Kun‐Ho Yoon, Pablo Arias et al. · Diabetes Care · 2014 · 223 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Lipoprotein Alterations, Hepatic Lipase Activity, and Insulin Sensitivity in Subclinical Hypothyroidism: Response to L-T ₄ Treatment

Gabriela Brenta, Gabriela Berg, Pablo Arias et al. · Thyroid · 2007 · 90 citations

Life Sciences, Biochemistry, Endocrinology +17

Trends and impacts of foreign investment in developing country agriculture: evidence from case studies.

P. Liu, Suffyanu S. Koroma, Pablo Arias et al. · 2013 · 63 citations

Agriculture, Agricultural Economics, Economics +16

Incidence of Hypoglycemic Episodes in Diabetic Patients Under Continuous Subcutaneous Insulin Infusion and Intensified Conventional Insulin Treatment: Assessment by Means of Semiambulatory 24-hour Continuous Blood Glucose Monitoring

Pablo Arias, W. Kerner, Horst Zier et al. · Diabetes Care · 1985 · 52 citations

Medicine, Internal Medicine, Diabetology +16